In vitro Assessment of the Biofield Treated Test Item on Cardiac Function Using Rat Cardiomyocytes Cell Line (H9c2) via Multiparametric Analysis

Journal: JOURNAL OF HYPERTENSION AND CARDIOLOGY PDF  Web

Published: Feb 14, 2019 Volume: 2 Issue: 1 Pages: 1-12

DOI: 10.14302/issn.2329-9487.jhc-19-2582 ISSN: 2329-9487

Authors: Mahendra Kumar Trivedi, Snehasis Jana

Citation: Mahendra Kumar Trivedi, Snehasis Jana (2019) In vitro Assessment of the Biofield Treated Test Item on Cardiac Function Using Rat Cardiomyocytes Cell Line (H9c2) via Multiparametric Analysis. Journal Of Hypertension And Cardiology - 2(4):1-12.

  • 86 Views
  • 6 Downloads

Abstract

Introduction: Heart disorders are the major concern of population health worldwide. According to WHO estimates 2018, 17.9 million peoples were died due to cardiovascular disorders.

Aim: The aim of this study was to investigate the cardioprotective activity of Biofield Energy Treated test item, Dulbecco's Modified Eagle Medium (DMEM) using rat cardiomyocytes (H9c2).

Methods: The test item (DMEM) was divided into three parts, first part received one-time Biofield Energy Treatment by a renowned Biofield Energy Healer, Mahendra Kumar Trivedi and was labeled as the one-time Biofield Energy Treated (BT-I) DMEM, while second part received the two-times Biofield Energy Treatment and is denoted as BT-II DMEM. The third part did not receive any treatment and defined as the untreated DMEM group.
Results: Cell viability of the test samples by 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) assay showed 89.03% and 98.49% in the BT-I and BT-II groups, respectively suggested a nontoxic and safe in nature of the tested test item. The BT-I group showed 16.01% restoration of cell viability. The level of lactate dehydrogenase (LDH) was significantly inhibited by 50.37% and 49.35% in the BT-I and BT-II groups, respectively compared to the untreated DMEM group. Moreover, percent protection of creatine kinase-myocardial band (CK-MB) by 49.48% and 59.79% in the BT-I and BT-II groups, respectively, compared to the untreated DMEM group. Reactive oxygen species (ROS) level in terms of mean fluorescence unit (FU) was reduced by 6.64% in the BT-I group than untreated DMEM. Besides, BT-I and BT-II groups significantly increased the level of % apoptotic cells by 63.16% and 97.37% (p≤0.05), respectively than untreated DMEM.

Conclusion: Allover, results envisaged that Biofield Treatment significantly improved different cardiac parameters. Thus, Biofield Energy Treatment (The Trivedi Effect®) could be utilized as a cardio-protectant against several cardiac disorders such as coronary artery disease, heart attack, arrhythmias, heart failure, congenital heart disease, cardiomyopathy, etc.

Conclusion

The study outcomes showed that the test substances were safe and non-toxic based on MTT cell viability assay with more than 89% viable cells. The one-time Biofield Energy Treated DMEM (BT-I) showed 16.01% cytoprotective activity. Further, increased level of lactate dehydrogenase (LDH) was significantly suppressed by 50.37% in the BT-I group, and 49.35% in the BT-II (two-times Biofield Energy Treated DMEM) group as compared to the untreated DMEM group. The cardio-specific enzyme, creatine kinase-myocardial band (CK-MB) was significantly inhibited by 49.48% and 59.79% in the BT-I and BT-II, respectively compared to the untreated DMEM group. Moreover, Reactive oxygen species (ROS) level in terms of mean fluorescence unit (FU) was reduced by 6.64% in the BT-I group than untreated DMEM. Percent apoptotic cells were significantly increased by 63.16% and 97.37% in the BT-I and BT-II, respectively compared to the untreated DMEM. In conclusion, The Biofield Energy Treatment significantly improved various cardiac parameters and protect cardiomyocytes cells from oxidative damage. Thus, it can be used as a complementary and alternative treatment for the prevention of various types of cardiac disorders viz. High blood pressure (hypertension), stroke, congestive heart failure (CHF), peripheral artery disease, congenital heart disease, rheumatic heart disease, valvular heart disease, carditis, thromboembolic disease, and venous thrombosis, etc. Further, it could be useful to improve cell-to-cell messaging, normal cell growth and differentiation, cell cycling and proliferation, neurotransmission, skin health, hormonal balance, immune and cardiovascular functions. Moreover, it can also be utilized in organ transplants (i.e., kidney, liver, and heart transplants), hormonal imbalance, aging, and various inflammatory and immune-related disease conditions like Alzheimer’s Disease (AD), Ulcerative Colitis (UC), Dermatitis, Asthma, Irritable Bowel Syndrome (IBS), Hashimoto Thyroiditis, Pernicious Anemia, Sjogren Syndrome, Multiple Sclerosis, Aplastic Anemia, Hepatitis, Graves’ Disease, Dermatomyositis, Diabetes, Parkinson’s Disease, Myasthenia Gravis,
Atherosclerosis, Systemic Lupus Erythematosus (SLE), stress, etc. with a safe therapeutic index to improve overall health and Quality of Life.